18F-匹佛罗司他PET/CT在194厘米长轴视野系统上前列腺癌的临床表现
该单中心回顾性研究纳入103例前列腺癌患者,在194厘米长轴视野(LAFOV)PET/CT系统上行18F-匹佛罗司他PET/CT,分析8分钟采集数据。结果显示总体阳性率88.3%,初诊分期患者全部阳性,复发患者阳性率80.3%;复发亚组中PSA与PET阳性显著相关(OR 7.40,AUC 0.912),且与阳性部位数相关(rho=0.620)。
要点
- 194厘米LAFOV PET/CT上18F-匹佛罗司他PET/CT总体阳性率88.3%。
- 初诊分期患者阳性率100%,复发患者阳性率80.3%。
- 复发患者中PSA与PET阳性及阳性部位数显著相关。
核心结论
- 18F-匹佛罗司他PET/CT在194厘米LAFOV PET/CT系统上对前列腺癌表现出高临床性能,复发时检出率与PSA水平密切相关,并能有效显示部位特异性病变分布。
研究设计与样本
- 回顾性单中心研究,连续纳入103例临床指征行18F-匹佛罗司他PET/CT的前列腺癌患者,均使用194厘米LAFOV PET/CT,仅分析8分钟采集数据集。
- 适应证包括初诊分期42例和疑似复发61例,PET findings按患者和预设解剖部位评估。
- 复发亚组中采用Mann-Whitney U检验、对数转换PSA的logistic回归、ROC分析和Spearman相关评估PSA与PET阳性的关联。
主要发现
- 总体PET阳性91/103例(88.3%),阴性8/103例(7.8%),不确定4/103例(3.9%)。
- 初诊分期患者全部阳性(42/42,100.0%),复发患者阳性49/61例(80.3%)。
- 最常见阳性部位为原发灶(57.3%)、淋巴结(35.0%)和骨(24.3%)。
- 复发患者中,PET阳性者PSA显著高于非阳性者(中位2.40 vs. 0.42 ng/mL,p < 0.001)。
- 对数转换PSA与PET阳性显著相关(OR 7.40,95% CI 2.18-25.11;p = 0.001),AUC为0.912(95% CI 0.828-0.974);PSA与阳性部位数相关(rho = 0.620,p < 0.001)。
临床怎么用
- 对于前列腺癌初诊分期或疑似复发患者,可考虑使用18F-匹佛罗司他PET/CT在LAFOV系统上评估病变分布。
- 复发患者中PSA水平有助于预测PET阳性概率及阳性部位数量,可辅助选择检查时机。
局限性
- 本研究为回顾性单中心设计,仅分析8分钟采集数据集,结果可能受选择偏倚影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess the clinical performance of [18F]piflufolastat PET/CT acquired on a total-body 194-cm LAFOV PET/CT system in patients with prostate cancer, with particular focus on detection rate, site-specific disease distribution, and the association between PET findings and serum PSA levels. METHODS: This retrospective single-centre study included 103 consecutive patients with prostate cancer who underwent clinically indicated [18F]piflufolastat PET/CT on 194-cm LAFOV PET/CT. Indications were primary staging (n = 42) or suspected recurrence (n = 61). Only the 8-min acquisition dataset was analyzed. PET findings were assessed on a patient basis and across predefined anatomical sites. In the recurrence subgroup, the association between PSA and PET positivity was evaluated using Mann-Whitney U test, logistic regression with log-transformed PSA, ROC analysis, and Spearman correlation with the number of positive sites. RESULTS: Overall, PET was positive in 91/103 patients (88.3%), negative in 8/103 (7.8%), and indeterminate in 4/103 (3.9%). Positivity was observed in all patients scanned for primary staging (42/42, 100.0%) and in 49/61 patients (80.3%) referred for recurrence. The most frequent positive sites were primary lesion (57.3%), lymph nodes (35.0%), and bone (24.3%). In recurrence, PSA was significantly higher in PET-positive than in non-positive cases (median 2.40 vs. 0.42 ng/mL, p < 0.001). Log-transformed PSA was significantly associated with PET positivity (OR 7.40, 95% CI 2.18-25.11; p = 0.001), with an AUC of 0.912 (95% CI 0.828-0.974). PSA also correlated with the number of positive sites (rho = 0.620, p < 0.001). CONCLUSION: [18F]piflufolastat PET/CT on 194-cm LAFOV PET/CT showed high clinical performance in prostate cancer, with strong PSA-dependent yield in recurrence and effective depiction of site-specific disease distribution.
引用
- Alongi P, Chiaravalloti A, Morea S, et al. Clinical performance of [18F]piflufolastat PET/CT on a 194-cm LAFOV PET/CT system in prostate cancer. Eur J Nucl Med Mol Imaging. 2026. PMID: 42216971. doi:10.1007/s00259-026-07955-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。